| __timestamp | Alnylam Pharmaceuticals, Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 17986000 |
| Thursday, January 1, 2015 | 60610000 | 32480000 |
| Friday, January 1, 2016 | 89354000 | 68081000 |
| Sunday, January 1, 2017 | 199365000 | 169906000 |
| Monday, January 1, 2018 | 382359000 | 248932000 |
| Tuesday, January 1, 2019 | 479005000 | 354100000 |
| Wednesday, January 1, 2020 | 588420000 | 433300000 |
| Friday, January 1, 2021 | 620639000 | 583300000 |
| Saturday, January 1, 2022 | 770658000 | 752700000 |
| Sunday, January 1, 2023 | 795646000 | 887600000 |
| Monday, January 1, 2024 | 975526000 | 1007200000 |
Unlocking the unknown
In the competitive landscape of biotechnology, understanding the financial strategies of leading companies is crucial. Over the past decade, Alnylam Pharmaceuticals and Neurocrine Biosciences have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Alnylam's SG&A expenses surged by approximately 1,700%, reflecting its aggressive expansion and marketing strategies. In contrast, Neurocrine's expenses increased by nearly 4,800%, indicating a robust investment in administrative and sales operations.
By 2023, Neurocrine's SG&A expenses slightly surpassed Alnylam's, marking a pivotal shift in their financial dynamics. This trend highlights the evolving priorities and growth strategies of these biotech giants. As the industry continues to innovate, monitoring such financial metrics provides valuable insights into the operational focus and market positioning of these companies.
Cost Management Insights: SG&A Expenses for Merck & Co., Inc. and Alnylam Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Sanofi or Neurocrine Biosciences, Inc.
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Neurocrine Biosciences, Inc.
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Pharming Group N.V. Trends and Insights
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Dynavax Technologies Corporation Trends and Insights
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Neurocrine Biosciences, Inc.
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Catalent, Inc. Trends and Insights
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and CRISPR Therapeutics AG
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Rhythm Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. and Mesoblast Limited: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Novavax, Inc.